🇺🇸 Natrecor in United States

FDA authorised Natrecor on 10 August 2001 · 374 US adverse-event reports

Marketing authorisations

FDA — authorised 10 August 2001

  • Application: NDA020920
  • Marketing authorisation holder: SCIOS LLC
  • Local brand name: NATRECOR
  • Indication: FOR SOLUTION — INTRAVENOUS
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Renal Failure — 51 reports (13.64%)
  2. Hypotension — 50 reports (13.37%)
  3. Injury — 44 reports (11.76%)
  4. Pain — 40 reports (10.7%)
  5. Unevaluable Event — 36 reports (9.63%)
  6. Cardiac Failure Congestive — 35 reports (9.36%)
  7. Anxiety — 33 reports (8.82%)
  8. Death — 32 reports (8.56%)
  9. Emotional Distress — 27 reports (7.22%)
  10. Fear — 26 reports (6.95%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Natrecor approved in United States?

Yes. FDA authorised it on 10 August 2001; FDA has authorised it.

Who is the marketing authorisation holder for Natrecor in United States?

SCIOS LLC holds the US marketing authorisation.